Literature DB >> 16018788

Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer.

D Pereg1, M Lishner.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs), both cyclooxygenase-2 (COX-2) selective and nonselective inhibitors, are amongst the most popular medications worldwide. Whilst their anti-inflammatory effect is well known, recent studies have demonstrated an unexpected effect in both the prevention and treatment of several types of cancer. The anticancerous effect of NSAIDs is believed to be mainly due to the inhibition of COX-2, which is overexpressed in many types of cancer and may play a major role in tumourigenesis. In this review, we will describe the possible mechanisms for NSAIDs anticancer effect and summarize the major clinical studies in cancer prevention and treatment. We will also discuss the effect of the recent reports of adverse cardiovascular effects on anticancer research of the selective COX-2 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16018788     DOI: 10.1111/j.1365-2796.2005.01519.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  30 in total

1.  Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia.

Authors:  Markus Jensen; Andreas Engert; Florian Weissinger; Wolfgang Knauf; Eva Kimby; Christopher Poynton; Ira Anton Oliff; Mathias J Rummel; Anders Osterborg
Journal:  Invest New Drugs       Date:  2007-12-20       Impact factor: 3.850

2.  A ceramide analog inhibits cPLA(2) activity and consequent PGE(2) formation in LPS-stimulated macrophages.

Authors:  Meir Goldsmith; Ala Daka; Nadia F Lamour; Roi Mashiach; Yifat Glucksam; Michael M Meijler; Charles E Chalfant; Tsaffrir Zor
Journal:  Immunol Lett       Date:  2010-10-30       Impact factor: 3.685

3.  The EP1 receptor for prostaglandin E2 promotes the development and progression of malignant murine skin tumors.

Authors:  Inok Surh; Joyce E Rundhaug; Amy Pavone; Carol Mikulec; Erika Abel; Melissa Simper; Susan M Fischer
Journal:  Mol Carcinog       Date:  2011-07-07       Impact factor: 4.784

Review 4.  Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence.

Authors:  Sarah Crawford
Journal:  Ther Adv Med Oncol       Date:  2014-03       Impact factor: 8.168

Review 5.  Roles for inflammation and regulatory T cells in colon cancer.

Authors:  Susan E Erdman; Theofilos Poutahidis
Journal:  Toxicol Pathol       Date:  2009-12-17       Impact factor: 1.902

6.  Risk of cancer among rheumatoid arthritis patients in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2009-01-28       Impact factor: 2.506

7.  Effect of phenytoin on celecoxib pharmacokinetics in patients with glioblastoma.

Authors:  Stuart A Grossman; Jeffrey Olson; Tracy Batchelor; David Peereboom; Glenn Lesser; Serena Desideri; Xiaobu Ye; Tarek Hammour; Jeffrey G Supko
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

8.  Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast.

Authors:  Min Hu; Guillermo Peluffo; Haiyan Chen; Rebecca Gelman; Stuart Schnitt; Kornelia Polyak
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-13       Impact factor: 11.205

9.  Knockout of the Bcmo1 gene results in an inflammatory response in female lung, which is suppressed by dietary beta-carotene.

Authors:  Yvonne G J van Helden; Sandra G Heil; Frederik J van Schooten; Evelien Kramer; Susanne Hessel; Jaume Amengual; Joan Ribot; Katja Teerds; Adrian Wyss; Georg Lietz; M Luisa Bonet; Johannes von Lintig; Roger W L Godschalk; Jaap Keijer
Journal:  Cell Mol Life Sci       Date:  2010-04-06       Impact factor: 9.261

10.  Polymorphisms in regulatory regions of cyclooxygenase-2 gene and breast cancer risk in Brazilians: a case-control study.

Authors:  Diogo N Piranda; Juliana S Festa-Vasconcellos; Laura M Amaral; Anke Bergmann; Rosane Vianna-Jorge
Journal:  BMC Cancer       Date:  2010-11-08       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.